Article
Pharmacology & Pharmacy
Ruxu You, Jinyu Liu, Lei Ke, Min Wan, Yu Zhang, Guangyi Yu, Takahiro Mori
Summary: This study found that sequential denosumab/zoledronic acid is cost-effective compared to zoledronic acid monotherapy for Chinese postmenopausal osteoporotic women over 70 years old.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Y. W. Choo, N. A. Mohd Tahir, M. S. Mohamed Said, S. C. Li, M. Makmor Bakry
Summary: The study compared the cost-effectiveness of denosumab with alendronate and no treatment for postmenopausal osteoporosis in the Malaysian population. The results indicate that denosumab is a cost-effective option for postmenopausal osteoporotic women aged 60 and older.
OSTEOPOROSIS INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Zora Messner, David Carro-Vazquez, Judith Haschka, Johannes Grillari, Heinrich Resch, Christian Muschitz, Peter Pietschmann, Jochen Zwerina, Matthias Hackl, Roland Kocijan
Summary: This study investigated circulating miRNAs as potential biomarkers for monitoring treatment response in women with postmenopausal osteoporosis on denosumab therapy. The results showed significant changes in expression of seven miRNAs after two years of treatment, which correlated with changes in bone mineral density and bone turnover markers.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Ben Johnson, Edward Chia-Cheng Lai, Huang-tz Ou, Hong Li, Bjorn Stollenwerk
Summary: The study evaluated the cost-effectiveness of continued denosumab treatment versus discontinuation after one dose for postmenopausal osteoporosis in Taiwan, based on real-world fracture reduction effectiveness and cost data. The results showed that continued denosumab treatment had an incremental cost-effectiveness ratio of USD $16,743 per QALY, indicating cost-effectiveness compared to discontinuation of treatment.
ARCHIVES OF OSTEOPOROSIS
(2021)
Article
Endocrinology & Metabolism
Tomaz Kocjan, Antonela Sabati Rajic, Andrej Janez, Gaj Vidmar, Nina Orehek, Janja Marc, Barbara Ostanek
Summary: This retrospective study compared bone mineral density changes in postmenopausal women with severe osteoporosis after stopping teriparatide therapy and receiving denosumab or bisphosphonates treatment for 12 months. The results showed that after 12 months, sequential denosumab treatment appeared to yield higher additional lumbar spine bone mineral density gain compared with bisphosphonates treatment.
ENDOCRINE PRACTICE
(2021)
Review
Pharmacology & Pharmacy
Yang Sun, Yue Li, Jiangbi Li, Xiaoping Xie, Feng Gu, Zhenjiang Sui, Ke Zhang, Tiecheng Yu
Summary: The study found that a combination treatment of teriparatide and denosumab in postmenopausal osteoporosis patients leads to greater increase in bone density compared to monotherapy, without significant difference in adverse events.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Orthopedics
Jiemei Gu, Hao Zhang, Qingyun Xue, Li Wang, Zhifeng Cheng, Yawei Zhang, Qifu Li, Lingqing Yuan, Yukun Li, Jin Dong, Yanan Huo, Xin Tang, Ling Hu, Xinjia Wang, Fei Hua, Lin Shen, Jinluo Cheng, Huimin Zhou, Youjia Xu, Tao Yang, Chuansuo Wang, Jin Xu, Jie Shen, Ying Zhang, Xiaomei Zhang, Dun Hong, Xiaoling Guan, Xinhua Xiao, Guang Wang, Yonghua Liu, Liujun Fu, Jianting Chen, Xigao Cheng, Yue Ding, Lijun Liu, Qi Yao, Xinchao Zhang, Lixin Li, Panjun Zhang, Chunying Deng, Chengyan Jiang, Li You, Kai Wang, Shimin Zhang, Jianzhong Xiao, Wei Liu, Xiaohong Du, Xianwen Shang, Tianrong Pan, Chen Lei, Shuren Guo, Zhenlin Zhang
Summary: This study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of a denosumab biosimilar (LY06006) in Chinese postmenopausal women with osteoporosis. The results showed that LY06006 significantly increased bone mineral density and reduced bone resorption. The safety and tolerability of LY06006 were comparable to the reference drug Prolia(R).
JOURNAL OF ORTHOPAEDIC TRANSLATION
(2023)
Review
Endocrinology & Metabolism
Y. Wan, F. Zeng, H. Tan, Y. Lu, Y. Zhang, L. Zhao, R. You
Summary: This paper reviewed and evaluated pharmacoeconomic studies of denosumab for osteoporosis. Denosumab was found to be more cost-effective in older patients with prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were applicable in improving the quality of pharmacoeconomic studies in osteoporosis.
OSTEOPOROSIS INTERNATIONAL
(2022)
Review
Pharmacology & Pharmacy
Yi Chen, Jun Zhu, Yiqin Zhou, Jinhui Peng, Bo Wang
Summary: Denosumab is a promising antiresorptive agent in postmenopausal women with osteoporosis or low bone mineral density, showing greater increase in bone mineral density and reduced fracture risk compared to placebo, without excess risks of adverse events.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Taewook Kang, Si Young Park, Soon Hyuck Lee, Jong Hoon Park, Seung Woo Suh
Summary: This study compared the effects of DEN and ZOL on postmenopausal women with osteoporosis and found that DEN was associated with greater increase in BMD and TBS, as well as greater inhibition of bone remodeling compared with ZOL.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Public, Environmental & Occupational Health
Ruxu You, Jinyu Liu, Lei Ke, Guangyi Yu, Yu Zhang, Takahiro Mori
Summary: The study found that sequential teriparatide/zoledronic acid is not cost-effective for Chinese women with postmenopausal osteoporosis, unless the cost of teriparatide is reduced by 50% for participants over the age of 80.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Delphine Farlay, Sebastien Rizzo, David W. Dempster, Shuang Huang, Arkadi Chines, Jacques P. Brown, Georges Boivin
Summary: In postmenopausal women with osteoporosis, denosumab therapy for 10 years significantly increased bone mineralization, with more pronounced changes within the first 5 years. The study showed that denosumab treatment for 5 years led to a transition of mineral to more mature crystals and lower microhardness, indicating a persistence of low bone remodeling state at 5 and 10 years.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Endocrinology & Metabolism
Karine Briot, Anne-Marie Schott, Jean-Philippe Sanchez, Jean-Vannak Chauny, Pascale Samama, Gaelle Desamericq
Summary: In a real-world clinical practice in France, postmenopausal women with osteoporosis showed high persistence with denosumab at 12 and 24 months, with a good tolerability profile.
Article
Endocrinology & Metabolism
Polyzois Makras, Maria P. Yavropoulou, Stergios A. Polyzos, Socrates E. Papapoulos, Danai Georgakopoulou, Athanasios Papatheodorou, Athanasios D. Anastasilakis
Summary: By measuring the serum TRAcP5b levels in postmenopausal women treated with denosumab for different durations, it was found that the serum TRAcP5b levels were not related to the duration of exposure to denosumab. Therefore, serum TRAcP5b is not an effective early marker for increased accumulation of osteoclasts and higher bone resorption risk in humans.
OSTEOPOROSIS INTERNATIONAL
(2023)
Article
Endocrinology & Metabolism
Ron Goeree, Natasha Burke, Manon Jobin, Jacques P. Brown, Donna Lawrence, Bjorn Stollenwerk, Damon Willems, Ben Johnson
Summary: This study shows that romosozumab followed by alendronate is a cost-effective treatment option for postmenopausal women with osteoporosis at high risk for fracture in Canada. It is associated with reduced costs and greater benefit compared to alendronate and risedronate alone.
ARCHIVES OF OSTEOPOROSIS
(2022)
Review
Endocrinology & Metabolism
Jemima E. Schadow, David Maxey, Toby O. Smith, Mikko A. J. Finnila, Sarah L. Manske, Neil A. Segal, Andy Kin On Wong, Rachel A. Davey, Tom Turmezei, Kathryn S. Stok
Summary: This study systematically reviewed the published parameters for assessing subchondral bone in human osteoarthritis using computed tomography. The study identified clinically meaningful parameter categories and emphasized the importance of quantification and standardized measurement methods for improving the evaluation of disease progression.
Article
Endocrinology & Metabolism
Lindsay L. Loundagin, Kim D. Harrison, Xuan Wei, David M. L. Cooper
Summary: This study developed new techniques to define zones of BMU activity based on the 3D morphology of remodeling spaces in rabbit cortical bone and integrated morphological data with the BMU longitudinal erosion rate (LER) to elucidate the spatial-temporal coordination of BMUs and estimate mineral apposition rate (MAR). The results showed that the manual and semi-automated methods accurately defined the zones of remodeling spaces, and these techniques have the potential to assess dynamic parameters of bone resorption and formation.
Article
Endocrinology & Metabolism
Soroush Masrouri, Farzad Esmaeili, Maryam Tohidi, Fereidoun Azizi, Farzad Hadaegh
Summary: This study examined the association between estimated glomerular filtration rate (eGFR) decline and fracture incidence. The results showed that rapid kidney function decline (RKFD) can increase the incidence of fractures among the general population.
Article
Endocrinology & Metabolism
Steven J. Meas, Gabriella M. Daire, Michael A. Friedman, Rachel Denapoli, Preetam Ghosh, Joshua N. Farr, Henry J. Donahue
Summary: Age- and disuse-related bone loss both lead to decreases in bone mineral density, cortical thickness, and trabecular thickness and connectivity. It is important to experimentally compare these two mechanisms at a structural and transcriptomic level to better understand their similarities and differences. This study compares the effects of hindlimb unloading and aging on bone microarchitecture and gene expression in mice, finding that while both induce similar changes, aging has a greater impact on the transcriptome and tissue level.
Correction
Endocrinology & Metabolism
Masaru Matsuoka, Sho Tsukamoto, Yuta Orihara, Rieko Kawamura, Mai Kuratani, Nobuhiko Haga, Kenji Ikebuchi, Takenobu Katagiri
Article
Endocrinology & Metabolism
Rachel Kohler, Amy Creecy, David R. Williams, Matthew R. Allen, Joseph M. Wallace
Summary: Osteogenesis imperfecta is a hereditary bone disease that weakens bones and increase fracture risk. Current interventions mainly focus on increasing bone mass, but the compromised tissue-level material properties are not addressed. A study found that a RAL analog could reduce fracture risk, but further development is needed for optimal results in patients with osteogenesis imperfecta.
Article
Endocrinology & Metabolism
So Jeong Park, Eunhye Ji, Hyun Ju Yoo, Kyunggon Kim, Sunghwan Ji, Ji Yeon Baek, Jin Young Lee, Hee-Won Jung, Il-Young Jang, Eunju Lee, Namki Hong, Beom-Jun Kim
Summary: The study analyzed the relationship between serum lumican levels and osteosarcopenia in older adults, showing that older adults with osteosarcopenia had lower serum lumican levels. Lower serum lumican levels were associated with reduced bone mass and grip strength, indicating that lumican levels could be used as a biomarker for assessing the risk of osteosarcopenia, osteoporosis, or sarcopenia in older adults.
Article
Endocrinology & Metabolism
Michael B. Chavez, Michelle H. Tan, Tamara N. Kolli, Natalie L. Andras, Brian L. Foster
Summary: This study revealed the complex mechanisms by which disabling BSP functional domains led to profound and distinct changes in cementoblast cell functions, including dysregulated gene expression and reduced mineralization.
Article
Endocrinology & Metabolism
Julien Seiller, Blandine Merle, Romain Fort, Emilie Virot, Solene Poutrel, Giovanna Cannas, Arnaud Hot, Roland Chapurlat
Summary: The purpose of this study was to assess the prevalence of bone fragility in sickle cell patients and to evaluate the potential risk factors and associated complications.
Article
Endocrinology & Metabolism
Chirantap Oza, Anuradha Khadilkar, Pranay Goel, Madhura Karguppikar, Nikhil Shah, Nikhil Lohiya, Shruti Mondkar, Prashant Patil, Hemchand Prasad, Ankita Maheshwari, Dipali Ladkat, Neha Kajale, Chidvilas More, Devarati Khurjekar, Vaman Khadilkar
Summary: This study revealed that BoneXpert (BX) can be used for accurate assessment of bone age and screening of bone health in Indian children and youth with type-1 diabetes (T1D). 51.5% of T1D subjects showed significantly decreased metacarpal index (MCI). Height, Tanner stage, and vitamin D concentrations were positively correlated with MCI, while HbA1c and disease duration were negatively correlated with MCI.
Article
Endocrinology & Metabolism
Mariam R. Farman, Catherine Rehder, Theodora Malli, Cheryl Rockman-Greenberg, Kathryn Dahir, Gabriel Angel Martos-Moreno, Agnes Linglart, Keiichi Ozono, Lothar Seefried, Guillermo del Angel, Gerald Webersinke, Francesca Barbazza, Lisa K. John, Sewmi M. A. Delana Mudiyanselage, Florian Hoegler, Erica Burner Nading, Erin Huggins, Eric T. Rush, Ahmed El-Gazzar, Priya S. Kishnani, Wolfgang Hoegler
Summary: The ALPL gene variant database serves as an archive for interpreting the clinical significance of ALPL gene variants, facilitating the reclassification of VUS and continuous updates. The project establishes an international expert consortium, providing a multidisciplinary collaboration framework to improve genetic counseling and medical decision-making for HPP patients.
Article
Endocrinology & Metabolism
Giovanni Adami, Davide Gatti, Maurizio Rossini, Alessandro Giollo, Matteo Gatti, Francesco Bertoldo, Eugenia Bertoldo, Amy S. Mudano, Kenneth G. Saag, Ombretta Viapiana, Angelo Fassio
Summary: Certain diseases requiring glucocorticoids are independently associated with an increased risk of fractures. Chronic obstructive pulmonary disease (COPD) and neurological diseases are associated with both vertebral and non-vertebral fracture risk, while rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are only associated with non-vertebral fractures.
Article
Endocrinology & Metabolism
Frank C. Ko, Rong Xie, Brandon Willis, Zoe G. Herdman, Bryan A. Dulion, Hoomin Lee, Chun-do Oh, Di Chen, D. Rick Sumner
Summary: Intramembranous bone regeneration is important in joint and tooth replacement, but its underlying mechanisms are not well understood. This study found that increased periostin gene expression preceded increases in osteogenic genes during bone regeneration. Using a genetic mouse model, the researchers discovered that cells transiently expressing periostin played a critical role in intramedullary intramembranous bone regeneration.
Article
Endocrinology & Metabolism
T. Savikangas, T. H. Suominen, M. Alen, T. Rantalainen, S. Sipila
Summary: Regular exercise, especially high-intensity physical activity, can help slow down age-related bone loss and prevent a decline in femoral neck bone mineral density.
Article
Endocrinology & Metabolism
Mishaela R. Rubin, Ruban Dhaliwal
Summary: The increased risk of fractures observed in adults with type 1 diabetes (T1D) cannot be solely explained by modest decreases in areal bone mineral density (BMD). Accumulation of advanced glycation endproducts (AGEs) in bone has been suggested as a possible cause for the increased bone fragility in diabetes. Although the evidence linking AGEs and fractures in individuals with T1D is limited, recent data show that AGEs, as measured by skin intrinsic fluorescence, are a risk factor for lower BMD in T1D. Further research is needed to determine if there is a causal relationship between fractures and AGEs in T1D. If confirmed, this could lead to interventions that can reduce AGE accumulation and ultimately reduce fractures in T1D patients.